$5.84B in CY2024 Part D spend433K claims · 75K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Enzalutamide used for?
XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensiti....
Is there a generic for Enzalutamide?
No. Enzalutamide is brand-only with no generic equivalents currently in market.
How much does my plan pay for Enzalutamide?
NADAC pricing data not currently available for this drug.
Is Enzalutamide on the FDA shortage list?
No. Enzalutamide is not currently on the FDA Drug Shortage Database.
7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.